Overview

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Treatments:
Mesalamine